Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab With or Without Radiation in First-Line Gastroesophageal Cancers
NCT04021108Phase 2Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Jul 2019
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in gastroesophageal adenocarcinoma, sponsored by Weill Cornell Medicine. Started Jul 2019; status: active, not recruiting.
02
Drugs
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT04021108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04021108.